Discovery of Clinical Candidate 1-{[(2S,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. Katherine L. Lee , Catherine M. Ambler , David R. Anderson , Brian P. Boscoe , Andrea G. Bree , Joanne I. Brodfuehrer , Jeanne S. Chang , Chulho Choi , Seungwon Chung , Kevin J. Curran , Jacqueline E. Day , Christoph M. Dehnhardt , Ken Dower , Susan E. Drozda , Richard K. Frisbie , Lori K. Gavrin , Joel A. Goldberg , Seungil Han , Martin Hegen , David Hepworth , Heidi R. Hope , Satwik Kamtekar , Iain C. Kilty , Arthur Lee , Ling , Frank E. Lovering , Michael D. Lowe , John P. Mathias , Heidi M. Morgan , Elizabeth A. Murphy , Nikolaos Papaioannou , Akshay Patny , Betsy S. Pierce , Vikram R. Rao , Eddine Saiah , Ivan J. Samardjiev , Brian M. Samas , Marina W. H. Shen , Julia H. Shin , Holly H. Soutter , Joseph W. Strohbach , Peter T. Symanowicz , Jennifer R. Thomason , John D. Trzupek , Richard Vargas , Fabien Vincent , Jiangli Yan , Christoph W. Zapf , Stephen W. Wright Journal of Medicinal Chemistry（2017）
AI 理解论文
溯源树
样例
